Alphabet Inc Class A vs Oruka Therapeutics Inc. Common Stock — how do they compare? Alphabet Inc Class A trades at $343.7 (market cap $4.23T), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B). The key difference: Alphabet Inc Class A is far larger — about 832.7× Oruka Therapeutics Inc. Common Stock's market cap, and Alphabet Inc Class A pays a 0.25% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 86 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| GOOGL | ORKA | |
|---|---|---|
Market Cap | $4.23T | $5.08B |
Volume | 27,871,114 | 685,276 |
Sector | Media | Health |
52-Week High | $402.62 | $113.08 |
52-Week Low | $250.46 | $26.19 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $4.12T | $4.21B |
Dividend Yield | 0.25% | — |
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $353.78, up 0.3% with strong technical momentum as price approaches resistance at $356. The stock shows robust fundamentals with Q2 2026 EPS beating expectations at $9.11 versus $2.87, continuing a pattern of earnings outperformance. Revenue growth accelerated to $402.84 billion in 2025 with net income margins expanding to 32.8%. Analyst sentiment remains overwhelmingly positive with 87% buy ratings and a $430.96 consensus target, though RSI levels suggest potential near-term overbought conditions.
Alphabet presents a compelling growth story with AI-driven expansion and strong financial execution. The primary investment opportunity lies in continued AI leadership and cloud growth, while risks include antitrust scrutiny and tech sector volatility. With valuation metrics remaining reasonable (P/E 17.75) despite strong performance, the stock offers balanced upside potential for long-term investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →